Dynavax Technologies reported $220.76M in Loan Capital for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Loan Capital Change
Abbvie ABBV:US $ 63522M 667M
Adma Biologics ADMA:US $ 138.42M 43.56M
Agenus AGEN:US $ 0M 12.82M
Amgen AMGN:US $ 36010M 2788M
AstraZeneca AZN:LN 28805M 83M
Astrazeneca AZN:US 28.81B 83M
Biogen BIIB:US $ 6275.7M 1.7M
Biomarin Pharmaceutical BMRN:US $ 1080.06M 0.98M
Bristol Myers Squibb BMY:US $ 37450M 2155M
Chimerix CMRX:US $ 0 0
Dynavax Technologies DVAX:US $ 220.76M 0.27M
Gilead Sciences GILD:US $ 25183M 4M
Glaxosmithkline GSK:US $ 29226M 8654M
Idera Pharmaceuticals IDRA:US $ 0M 0M
Merk MRK:US $ 30586M 104M
Minerva Neurosciences NERV:US $ 0M 0M
Nektar Therapeutics NKTR:US $ 0M 0M
Neurocrine Biosciences NBIX:US $ 377.7M 42.6M
Novartis NOVN:VX SF 24373M 150M
Pfizer PFE:US $ 35656M 539M
Regeneron Pharmaceuticals REGN:US $ 2700.4M 720.4M
Sarepta Therapeutics SRPT:US $ 1098.85M 1.97M
Tg Therapeutics TGTX:US $ 67.25M 0.46M
Vertex Pharmaceuticals VRTX:US $ 495.5M 14.3M